Non Small-Cell Lung Cancer Market Boost by 2023| Top players are Pfizer, Roche, AstraZeneca, Eli Lily, GlaxoSmithKline, Novartis AG, Merck & Co., and Agennix AG

Non-small cell Lung cancer is the malignant tissue formation in the lung, usually in the cell lining air passage, which is characterized by abnormal cell growth in lung tissue. Globally, lung cancer is one of the leading causes of death since the past several decades. According to the American lung association, the number of deaths due to lung cancer has increased ~3.5% from ~152,156 cases in 1999 to ~157,499 in 2012.

Get the Sample Report: https://www.alliedmarketresearch.com/request-toc-and-sample/666?utm_source=openpr&utm_medium=Niranjan

Furthermore, it is estimated that ~158,040 Americans are would die due to lung cancer by 2015. According to the American Society of cancer, non-small-cell lung cancer accounts for ~85% to 90% of overall lung cancer cases and the trend is expected to grow with the same momentum. Thus, a large patient base of non-small-cell lung cancer depicts the unmet need for diagnosis and treatment. It has been observed that non-small-cell lung cancer is the most prevalent type of lung cancer commonly caused due to active and passive smoking.

Conventionally, the treatment pattern for non-small cell lung cancer is focussed around chemotherapy. Surgery is not suitable for most of the people diagnosed with lung cancer, thus, chemotherapy remains the cornerstone for non-small cell lung cancer treatment. However, the emergence of targeted therapies for patients has widened the scope of NSCLC treatment by providing lesser side effects and effective treatments as compared to chemotherapy.

The launch of new drugs in several new drugs classes would address the potential unmet need among NSCLC patients over the forecast period. The potential drivers for lung cancer therapeutics market include active & passive tobacco smoking, geriatric population, and improper lifestyle. However, the availability of generic drugs, limited treatment options and unmet need of diagnosis might hamper the market. Chemotherapy and radiation therapy poses a bigger challenge in terms of adverse effects arising from treatment. Thus, key players have shifted their focus toward innovative therapies and safer therapeutics. For example, on April 20, 2015, global strategic partner Pfizer and Merck initiated the phase III study for Avelumb, to assess its safety and efficacy as compared to docetaxel in the patients with non-small cell lung cancer.

Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/666?utm_source=openpr&utm_medium=Niranjan

Global non-small-cell lung cancer market is segmented into types, therapeutics, and geography. Based on the types, global non-small-cell lung cancer market is further segmented into squamous cell carcinoma, adenocarcinoma, large cell carcinoma and others. The market is segmented on the basis of therapeutics into chemotherapy, targeted therapy, surgery, radiotherapy, and pipeline drugs. Furthermore, the market is segmented, on the basis of geography, across North America, Europe, Asia-Pacific and LAMEA. Key players profiled in the market are Pfizer, Roche, AstraZeneca, Eli Lily, GlaxoSmithKline, Novartis AG, Merck & Co., and Agennix AG. Collaboration, product launch and acquisition are some of the strategies adopted by key players in the non-small cell lung cancer market. For example, on April 21, 2015, Pfizer received the USFDA approval for potential treatment of patients with ROS1-positive non-small cell lung cancer. On November 21, 2014, GSK collaborated with Clovis oncology to design clinical trials for the evaluation of new combination therapy used in NSCLC treatments.

KEY MARKET BENEFITS

The report provides a quantitative analysis of the current market and estimations through 2014‐2020 that help identify the prevailing market opportunities

Non small cell lung cancer market conditions are comprehensively analyzed based on region

Key market players within the non small cell lung cancer market are profiled in the report and their strategies are analyzed thoroughly, which helps in understanding the competitive outlook of the market

Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework

Comprehensive analysis of factors that drive and restrict the growth of the global non-small cell lung cancer market, is provided in the report

The exhaustive analysis of the global non-small cell lung cancer devices market by therapeutics type helps in understanding the types of therapeutics that are currently being used along with the variants that would gain prominence in future

KEY MARKET SEGMENTS

Global non small-cell lung cancer market is segmented as below:

Global non small-cell lung cancer market- by Type
Squamous cell (epidermoid) carcinoma
Adenocarcinoma
Large cell (undifferentiated) carcinoma
Other

Global non small-cell lung cancer market- by Therapy
Chemotherapy
Targeted therapy
Surgery
Radiotherapy
Laser therapy
Photodynamic therapy (PDT)
Others

Global non small-cell lung cancer market- by Geography
North America
Europe
Asia-Pacific
LAMEA

About Us:-

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.